Alt-Data Signal Hub

BAX

Baxter International Inc. · $26.16 (-2.2%) · mkt cap $13.5B

6 hub catalysts across 4 sources · backtest → · ← Ticker Explorer

Analyst Ratings (Upgrades/Downgrades)FINRA Short VolumeFDA Approvals & RecallsSEC EDGAR Filings

Signal summary

Signals diverge

Bullish and bearish forces are in conflict here — weigh both columns.

97± Mixedconviction from hub signals

Bullish factors

FDA approval
1 analyst upgrade

Bearish factors

4 analyst downgrades

Context (not directional): Short volume 1% of float-traded

Signal mix for BAX

Which data feeds have fired on this name — hover a slice for counts.

Best strategy

2-yr backtest · by Sharpe

Donchian Breakout has fit BAX best over 2 years (+69.8%, Sharpe 0.85). Historical/in-sample — walk-forward all 19 →

#	Strategy	Return	Sharpe	Beats B&H
1	Donchian Breakout	+69.8%	0.85	✓
2	SMA Crossover	+55.0%	0.75	✓
3	Price vs 200-day MA	+49.5%	0.74	✓

Price — 1 year

daily close

Analyst ratings

live · 5 changes

Date	Action	Analyst	Rating Change
2026-07-31	Upgrade	Citigroup	Sell → Neutral
2026-05-28	Downgrade	Citigroup	Neutral → Sell
2025-10-31	Downgrade	Argus Research	Buy → Hold
2025-08-04	Downgrade	Stifel	Buy → Hold
2024-07-15	Downgrade	Morgan Stanley	Equal-Weight → Underweight

Catalyst timeline

6 hub signals

Date	Source	Event	Entity	Value
2026-07-30	SEC EDGAR Filings	8-K Event	BAXTER INTERNATIONAL INC		source ↗
2026-07-30	FINRA Short Volume	Short Vol	BAX	61% short	source ↗
2026-07-14	SEC EDGAR Filings	8-K Event	BAXTER INTERNATIONAL INC		source ↗
2026-06-29	FDA Approvals & Recalls	FDA Approval	FDA approved PerClot® Polysaccharide Hemostatic System — Baxter Healthcare Corporation	approval	source ↗
2026-06-10	FINRA Short Volume	Short Vol	BAX	67% short	source ↗
2026-05-28	Analyst Ratings (Upgrades/Downgrades)	Analyst Downgrade	Citigroup: Downgrade (Neutral → Sell)		source ↗